| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(10)70226-6 |
| P953 | full work available online at | https://api.elsevier.com/content/article/PII:S1470204510702266?httpAccept=text/xml |
| https://api.elsevier.com/content/article/PII:S1470204510702266?httpAccept=text/plain | ||
| P698 | PubMed publication ID | 20851683 |
| P2093 | author name string | Martin Schlumberger | |
| P2860 | cites work | Motesanib diphosphate in progressive differentiated thyroid cancer. | Q34791480 |
| Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. | Q35023367 | ||
| New therapeutic approaches for metastatic thyroid carcinoma | Q36724334 | ||
| Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. | Q37782505 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 912-913 | |
| P577 | publication date | 2010-09-17 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Kinase inhibitors for refractory thyroid cancers | |
| P478 | volume | 11 |
| Q40820078 | New targeted therapies for thyroid cancer |
| Q94465339 | Precision Medicine in Non Communicable Diseases |
| Q37979656 | RET TKI: potential role in thyroid cancers. |
| Q38118647 | Sorafenib and Thyroid Cancer |
| Q36788057 | Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer |
| Q57828027 | The Use of Sorafenib in the Thyroid Cancer |
Search more.